Evidence map›Paper›PMID 42118253›Full record

ArticleEuropean spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society2026

Bioactive glass-ceramic spacer alone versus spacer augmented with ABM/P-15 in single-level ACDF: a retrospective cohort study comparison of fusion rates and clinical outcomes.

Je Hwi Yun, Sung Hyeon Noh, Sang Hyun Kim, Bong Ju Moon, Pyung Goo Cho

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Je Hwi YunDepartment of Neurosurgery, Ajou University Medical Center, Suwon-si, Gyeonggi-do, Republic of Korea.
Sung Hyeon NohDepartment of Neurosurgery, Ajou University Medical Center, Suwon-si, Gyeonggi-do, Republic of Korea.
Sang Hyun KimDepartment of Neurosurgery, Ajou University Medical Center, Suwon-si, Gyeonggi-do, Republic of Korea.
Bong Ju MoonDepartment of Neurosurgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea. bongjumoon@gmail.com.
Pyung Goo ChoDepartment of Neurosurgery, Ajou University Medical Center, Suwon-si, Gyeonggi-do, Republic of Korea. nsdrcpg@ajou.ac.kr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAchieving early fusion is a critical goal when selecting graft material for anterior cervical discectomy and fusion (ACDF). As bioactive glass-ceramic (BGC-7) cages demonstrate favorable osteoconductive properties, their fusion potential may be enhanced through augmentation with osteoinductive materials. We hypothesized that the synergistic combination of BGC-7 with anorganic bone mineral enhanced with P-15 peptide (ABM/P-15) would lead to optimized fusion outcomes.

methodsThis retrospective cohort study analyzed 96 patients who underwent single-level ACDF. Fifty-five patients received a BGC-7 cage packed with ABM/P-15 (IF Group), and 41 received a BGC-7 cage alone (NO Group). Fusion was assessed using both computed tomography (CT)-based Bridwell grading and dynamic radiography at 6- and 12-months post operation. Clinical outcomes were evaluated using Visual Analog Scale score, Japanese Orthopedic Association scores, and Short Form-36. In the IF group, absorbable bone hemostat was applied to seal both cage apertures after ABM/P-15 placement to prevent graft migration during impaction.

resultsThe IF group demonstrated significantly higher fusion rates at 6 months (65.5% vs. 41.5%, p = 0.024), with a trend approaching statistical significance at 12 months (92.7% vs. 78.0%, p = 0.067). Multivariate analysis identified ABM/P-15 as an independent predictor of fusion (odds ratio (OR) = 3.93, 95% confidence interval (CI): 1.03-14.95, p = 0.044) after adjusting for smoking, diabetes, hypertension, age, and sex. The IF group demonstrated significantly higher segmental stability based on interspinous motion analysis at 6 months (69.1% vs. 46.3%, p = 0.035), with a trend approaching statistical significance at 12 months (92.7% vs. 78.0%, p = 0.067). Additionally, topographical analysis revealed that fusion was significantly enhanced in the central zone of the cage where the ABM/P-15 was applied. Clinical scores showed meaningful improvement but without significant differences between the two groups. No cases of iatrogenic heterotopic ossification were observed in either group, and no statistically significant differences in the incidence of other serious complications were observed.

conclusionABM/P-15 augmentation in BGC-7 cages accelerates early fusion progression, with a trend toward higher final fusion rates in single-level ACDF. Multivariate analysis further suggested ABM/P-15 as an independent predictor of fusion. A favorable safety profile, including zero incidence of cage subsidence and heterotopic ossification, supports this combination as a beneficial approach in cervical fusion surgery especially for patients at higher risk of nonunion.

Indexed as

CeramicsCervical VertebraeDiskectomyPeptide FragmentsSpinal FusionAdultCohort StudiesCollagenFemaleHumansMaleMiddle AgedRetrospective StudiesSilicatesTreatment Outcomecell-binding peptide P-15CollagenGlass ceramicsPeptide FragmentsSilicatesABM/P-15ACDFBGC-7Clinical outcomeFusion progressionHeterotopic ossification

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.